Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Brief Summary: The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.


Options:
A: Arm Label: Placebo/FOLFIRI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Arm Label: Aflibercept/FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Placebo/FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin); Assigned to Arm(s): Aflibercept/FOLFIRI
B: Arm Label: FOLFIRI + Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Arm Label: FOLFIRI + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Irinotecan, Drug: Folinic Acid, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): FOLFIRI + Ramucirumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): FOLFIRI + Placebo | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: Folinic Acid; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FOLFIRI + Placebo, FOLFIRI + Ramucirumab
C: Arm Label: TAS-102; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1: 5-FU + RT; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2: 5-FU + RT + Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: fluorouracil, Drug: oxaliplatin, Radiation: radiation therapy | Arm Label: Arm 3: Capecitabine + RT; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Radiation: radiation therapy | Arm Label: Arm 4: Capecitabine + RT + Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: oxaliplatin, Radiation: radiation therapy | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 3: Capecitabine + RT, Arm 4: Capecitabine + RT + Oxaliplatin | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1: 5-FU + RT, Arm 2: 5-FU + RT + Oxaliplatin | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): Arm 2: 5-FU + RT + Oxaliplatin, Arm 4: Capecitabine + RT + Oxaliplatin | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1: 5-FU + RT, Arm 2: 5-FU + RT + Oxaliplatin, Arm 3: Capecitabine + RT, Arm 4: Capecitabine + RT + Oxaliplatin

Answer: B